keyword
MENU ▼
Read by QxMD icon Read
search

Risperidone cognitive functioning

keyword
https://www.readbyqxmd.com/read/29736018/evaluation-of-fronto-striatal-networks-during-cognitive-control-in-unmedicated-patients-with-schizophrenia-and-the-effect-of-antipsychotic-medication
#1
Elyse J Cadena, David M White, Nina V Kraguljac, Meredith A Reid, Adrienne C Lahti
To understand the mechanism of cognitive control dysfunction in schizophrenia, it is critical to characterize brain function without the confounding effect of medication. It is also important to establish the extent to which antipsychotic medication restores brain function and whether those changes are related to psychosis improvement. Twenty-two patients with schizophrenia, initially unmedicated and after a 6-week course of risperidone, and 20 healthy controls (HC) studied twice, 6 weeks apart, performed an fMRI task...
May 7, 2018: NPJ Schizophrenia
https://www.readbyqxmd.com/read/29701957/a-novel-m1-pam-vu0486846-exerts-efficacy-in-cognition-models-without-displaying-agonist-activity-or-cholinergic-toxicity
#2
Jerri M Rook, Jeanette L Bertron, Hyekyung P Cho, Pedro M Garcia-Barrantes, Sean P Moran, James T Maksymetz, Kellie D Nance, Jonathan W Dickerson, Daniel H Remke, Sichen Chang, Joel Harp, Anna L Blobaum, Colleen M Niswender, Carrie K Jones, Shaun R Stauffer, P Jeffrey Conn, Craig W Lindsley
Selective activation of the M1 subtype of muscarinic acetylcholine receptor, via positive allosteric modulation (PAM), is an exciting strategy to improve cognition in schizophrenia and Alzheimer's disease patients. However, highly potent M1 ago-PAMs, such as MK-7622, PF-06764427, and PF-06827443, can engender excessive activation of M1, leading to agonist actions in the prefrontal cortex (PFC) that impairs cognitive function, induces behavioral convulsions, and results in other classic cholinergic adverse events (AEs)...
April 27, 2018: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/29568276/effects-of-continuing-oral-risperidone-vs-switching-from-risperidone-to-risperidone-long-acting-injection-on-cognitive-function-in-stable-schizophrenia-patients-a-pilot-study
#3
Hikaru Hori, Asuka Katsuki, Kiyokazu Atake, Reiji Yoshimura
Objectives: Risperidone is the first new generation antipsychotic drug to become available as a long-acting injection (LAI). The purpose of this study was to evaluate the effects of switching from oral risperidone to risperidone LAI (RLAI) on cognitive function in stable schizophrenia patients compared with the effects of continuing oral risperidone. Methods: Sixteen stable patients who had received risperidone monotherapy for at least 3 months were enrolled (the RLAI group)...
2018: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29548911/involvement-of-gabaergic-bdnf-and-nox-2-mechanisms-in-the-prevention-and-reversal-of-ketamine-induced-schizophrenia-like-behavior-by-morin-in-mice
#4
Benneth Ben-Azu, Adegbuyi Oladele Aderibigbe, Abayomi Mayowa Ajayi, Aya-Ebi Okubo Eneni, Solomon Umukoro, Ezekiel O Iwalewa
GABAergic (Gamma-aminobutyric acid) and neurotrophic derangements have important implication in schizophrenia, a neuropsychiatric disease. Previous studies have shown that nicotinamide adenine dinucleotide phosphate oxidase (NADPH-oxidase) alters GABAergic and neurotrophic activities via inflammatory and oxidative pathways. Thus, it has been proposed that agents with anti-oxidant and anti-inflammatory properties might be beneficial for the treatment of the disease. Morin is neuroactive bioflavonoid compound, which has been reported to demonstrate antipsychotic and anti-oxidant/anti-inflammatory activities...
May 2018: Brain Research Bulletin
https://www.readbyqxmd.com/read/29493377/dose-reduction-of-risperidone-and-olanzapine-can-improve-cognitive-function-and-negative-symptoms-in-stable-schizophrenic-patients-a-single-blinded-52-week-randomized-controlled-study
#5
Yanling Zhou, Guannan Li, Dan Li, Hongmei Cui, Yuping Ning
BACKGROUND: The long-term effects of dose reduction of atypical antipsychotics on cognitive function and symptomatology in stable patients with schizophrenia remain unclear. We sought to determine the change in cognitive function and symptomatology after reducing risperidone or olanzapine dosage in stable schizophrenic patients. METHODS: Seventy-five stabilized schizophrenic patients prescribed risperidone (≥4 mg/day) or olanzapine (≥10 mg/day) were randomly divided into a dose-reduction group ( n=37) and a maintenance group ( n=38)...
May 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29481966/value-encoding-in-the-globus-pallidus-fmri-reveals-an-interaction-effect-between-reward-and-dopamine-drive
#6
Vincenzo G Fiore, Tobias Nolte, Francesco Rigoli, Peter Smittenaar, Xiaosi Gu, Raymond J Dolan
The external part of the globus pallidus (GPe) is a core nucleus of the basal ganglia (BG) whose activity is disrupted under conditions of low dopamine release, as in Parkinson's disease. Current models assume decreased dopamine release in the dorsal striatum results in deactivation of dorsal GPe, which in turn affects motor expression via a regulatory effect on other nuclei of the BG. However, recent studies in healthy and pathological animal models have reported neural dynamics that do not match with this view of the GPe as a relay in the BG circuit...
June 2018: NeuroImage
https://www.readbyqxmd.com/read/29379293/efficacy-and-safety-profile-of-paliperidone-palmitate-injections-in-the-management-of-patients-with-schizophrenia-an-evidence-based-review
#7
REVIEW
Robin Emsley, Sanja Kilian
The course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and occupational functional impairments. Nonadherence to antipsychotic medication is a major determinant of this poor outcome. Long-acting injectable antipsychotics were developed specifically to address the nonadherence problem and are increasingly considered as an early treatment option, in an attempt to prevent accruing morbidity. This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29249806/cortical-high-gamma-network-oscillations-and-connectivity-a-translational-index-for-antipsychotics-to-normalize-aberrant-neurophysiological-activity
#8
A Ahnaou, H Huysmans, T Van de Casteele, W H I M Drinkenburg
Oscillatory activity in the gamma frequency range is a critical mechanism, which integrates neural networks within and across brain structures during cognitive processes. In schizophrenia, abnormalities in high gamma oscillations are ubiquitous and most likely reflect dysfunction in neuronal networks. In conscious rats, disturbed network oscillations associated with positive symptoms and cognitive deficits were modeled in different cortical areas by the dopaminergic agonist (amphetamine) and the N-methyl-D-aspartate (NMDA) receptor antagonists (PCP and MK801)...
December 18, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/29175423/tropisetron-enhances-recognition-memory-in-rats-chronically-treated-with-risperidone-or-quetiapine
#9
Indrani Poddar, Patrick M Callahan, Caterina M Hernandez, Xiangkun Yang, Michael G Bartlett, Alvin V Terry
While impairments of cognition in schizophrenia have the greatest impact on long-term functional outcome, the currently prescribed treatments, antipsychotic drugs (APDs), do not effectively improve cognition. Moreover, while more than 20 years have been devoted to the development of new drugs to treat cognitive deficits in schizophrenia, none have been approved to date. One area that has not been given proper attention at the preclinical or clinical stage of drug development is the chronic medication history of the test subject...
November 24, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29152440/risperidone-induced-amenorrhea-in-floridly-psychotic-female
#10
Shanila Shagufta, Faiza Farooq, Ali M Khan, Kamil Dar, Abdul Mohit
Despite the high prevalence of hyperprolactinemia in patients receiving antipsychotic medications, its side effects are often neglected. In patients receiving risperidone, the incidence of menstrual abnormalities is relatively small. Our patient was a 44-year-old, Haitian female whose total course of hospitalization was nine months, during most of which she remained floridly psychotic with low cognitive function with waxing and waning symptoms. She developed hyperprolactinemia and amenorrhea on risperidone...
September 13, 2017: Curēus
https://www.readbyqxmd.com/read/29037878/risperidone-ameliorates-cognitive-deficits-promotes-hippocampal-proliferation-and-enhances-notch-signaling-in-a-murine-model-of-schizophrenia
#11
Fen Xue, Yun-Chun Chen, Cui-Hong Zhou, Ying Wang, Min Cai, Wen-Jun Yan, Rui Wu, Hua-Ning Wang, Zheng-Wu Peng
Antipsychotic agents have been reported to promote hippocampal neurogenesis and improve cognitive deficits; yet, the molecular mechanisms underlying these actions remain unclear. In the present study, we used a murine model of schizophrenia induced by 5-day intraperitoneal injection with the non-competitive N-methyl-d-aspartate receptor antagonist MK801 (0.3mg/kg/day) to assess cognitive behavioral deficits, changes in Notch signaling, and cellular proliferation in the hippocampus of adult male C57BL/6 mice after 2-week administration of risperidone (Rip, 0...
October 14, 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28827871/cognitive-effects-with-rivastigmine-augmentation-of-risperidone-a-12-month-randomized-double-blind-placebo-controlled-study-in-schizophrenia
#12
Pattath Narayanan Suresh Kumar, Seema P Mohemmedali, P K Anish, Chittaranjan Andrade
OBJECTIVE: An important challenge in schizophrenia therapeutics is to develop an efficacious treatment for cognitive impairment. Acetylcholinesterase inhibitors, such as rivastigmine, have been studied for improving cognitive performance in these patients. MATERIALS AND METHODS: Rivastigmine (uptitrated to 6 mg/day) was given as an add-on therapy to risperidone-treated stable schizophrenia patients in a randomized, double-blind, placebo-controlled design. Of 67 patients who met eligibility criteria, 55 were recruited into the study...
April 2017: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/28721057/safety-tolerability-and-risks-associated-with-first-and-second-generation-antipsychotics-a-state-of-the-art-clinical-review
#13
REVIEW
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll, André F Carvalho
Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients - psychosocial functioning, quality of life, and recovery...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28538871/what-do-cochrane-systematic-reviews-say-about-interventions-for-autism-spectrum-disorders
#14
REVIEW
Larissa Lyra, Luiz Eduardo Rizzo, Camila Sá Sunahara, Daniela Vianna Pachito, Carolina de Oliveira Cruz Latorraca, Ana Luiza Cabrera Martimbianco, Rachel Riera
CONTEXT AND OBJECTIVE: Autism spectrum disorders (ASDs) include autistic disorder, Asperger's disorder and pervasive developmental disorder. The manifestations of ASDs can have an important impact on learning and social functioning that may persist during adulthood. The aim here was to summarize the evidence from Cochrane systematic reviews on interventions for ASDs. DESIGN AND SETTING: Review of systematic reviews, conducted within the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo...
March 2017: São Paulo Medical Journal, Revista Paulista de Medicina
https://www.readbyqxmd.com/read/28347257/antipsychotic-treatment-of-schizotypy-and-schizotypal-personality-disorder-a-systematic-review
#15
REVIEW
Klaus Damgaard Jakobsen, Eva Skyum, Nasseh Hashemi, Ole Schjerning, Anders Fink-Jensen, Jimmi Nielsen
Schizotypal personality disorder (SPD) is characterised by thought disorders, experiences of illusions, obsessive ruminations, bizarre or eccentric behaviour, cognitive problems and deficits in social functioning - symptoms that SPD shares with schizophrenia. Efforts have been undertaken to investigate the relationship between these conditions regarding genetics, pathophysiology, and phenomenology. However, treatment of SPD with antipsychotics has received less scientific attention. Embase and PubMed databases were searched using all known generic names of antipsychotics as search terms in combination with the following diagnostic terms: latent schizophrenia, schizotypal disorder, latent type schizophrenia, or SPD...
April 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28141710/the-curse-of-the-dolphins-cognitive-decline-and-psychosis
#16
Randall Phelps, Anne Tsai, Arlene Hagen, Joseph Pinter, Raegan Smith, Martin T Stein
Isela is an 11-year-old Mexican-American girl with mild intellectual disability. During a vacation with her family, she went swimming with dolphins. A few days later, Isela awoke at night with laughing spells; during the day, she was pacing, aggressive, and had a decline in self-care and communication skills. Her parents attributed the symptoms to the dolphins. She was evaluated by a pediatric neurologist. The sleep-deprived electroencephalogram, brain magnetic resonance imaging, lumbar puncture, and thyroid function tests were normal...
February 2017: Journal of Developmental and Behavioral Pediatrics: JDBP
https://www.readbyqxmd.com/read/28096678/risperidone-improves-interpersonal-perception-and-executive-function-in-patients-with-schizophrenia
#17
Zhenhe Zhou, Yuanyuan Zhu, Jun Wang, Hongmei Zhu
OBJECTIVE: To investigate whether risperidone improves social cognitive impairments and executive dysfunction in people with schizophrenia. METHODS: Fifty-six patients who met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, diagnostic criteria for schizophrenia were allocated to a risperidone treatment group (RTG, n=28) and a typical antipsychotic treatment group (TATG, n=28). Twenty-eight healthy volunteers were recruited as the normal control group (NCG)...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28062214/in-utero-exposure-to-atypical-antipsychotic-drug-risperidone-effects-on-fetal-neurotoxicity-in-hippocampal-region-and-cognitive-impairment-in-rat-offspring
#18
K P Singh, Manoj Kr Singh
Clinical studies indicate that about one-third of pregnant women with psychotic symptoms are exposed to either typical or atypical antipsychotic drugs (APDs). Reports on prenatal subject/model are lacking hence, the present study was undertaken to investigate the effect of prenatal exposure to risperidone (RIS) on the fetal hippocampus, and their related functional changes in young rat offspring. In this study, pregnant Wistar rats were exposed to equivalent therapeutic doses of RIS at 0.8mg/kg, 1.0mg/kg, and 2...
April 3, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28003154/antipsychotics-influence-toll-like-receptor-tlr-expression-and-its-relationship-with-cognitive-functions-in-schizophrenia
#19
Szabolcs Kéri, Csilla Szabó, Oguz Kelemen
Increasing evidence suggests that altered immune functions are related to the pathophysiology of schizophrenia. Relatively little information is available on Toll-like receptors (TLRs), which are implicated in the recognition of molecular patterns associated with pathogens and internal cellular damage signals. By using immunophenotyping and flow cytometry, we investigated TLRs in CD14+ monocytes, CD4+CD25+Foxp3+ regulatory T cells (Treg), and CD3+CD4+CD25+ activated T cells (Tact) in 35 drug-naïve patients with schizophrenia before and after an 8-week period of antipsychotic treatment with risperidone or olanzapine...
December 19, 2016: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/27988871/current-pharmacological-approaches-to-reduce-chorea-in-huntington-s-disease
#20
REVIEW
Emma M Coppen, Raymund A C Roos
There are currently no effective pharmacological agents available to stop or prevent the progression of Huntington's disease (HD), a rare hereditary neurodegenerative disorder. In addition to psychiatric symptoms and cognitive impairments, HD causes progressive motor disturbances, in particular choreiform movements, which are characterized by unwanted contractions of the facial muscles, trunk and extremities. Management of choreiform movements is usually advised if chorea interferes with daily functioning, causes social isolation, gait instability, falls, or physical injury...
January 2017: Drugs
keyword
keyword
29570
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"